
Quarterly ResultJul 30, 2026, 04:07 PM
Myriad Genetics Q2 Revenue Down 11% to $190.7M; Revises FY26 Guidance
AI Summary
Myriad Genetics reported second-quarter 2026 revenue of $190.7 million, an 11% decrease year-over-year, resulting in a net loss of $43.2 million. The company revised its full-year 2026 revenue guidance lower to $770-$790 million, citing challenges in Prenatal Health and increased payer friction. Despite the financial downturn, Myriad launched new products like Prolaris + AI and FirstGene, expanded its Precise MRD offerings, and initiated strategic efficiency programs to drive future growth and profitability.
Key Highlights
- Q2 2026 revenue decreased 11% year-over-year to $190.7 million.
- Reported Q2 2026 net loss of $43.2 million, or $(0.46) per share.
- Adjusted Q2 2026 net loss was $(23.4) million, or $(0.25) per share.
- Cancer Care Continuum revenue was $114.1 million, down 11% YoY, with volume up 8%.
- Prenatal Health revenue was $39.8 million, down 16% YoY, with volume down 9%.
- Mental Health revenue was $36.8 million, down 3% YoY, with volume up 4%.
- Revised full-year 2026 revenue guidance to $770-$790 million.
- Launched Prolaris + AI for prostate cancer and FirstGene Multiple Prenatal Screen.
Price Impact
More from MYGN